Recursion Pharmaceuticals (RXRX) Depreciation and Depletion (2020 - 2024)
Recursion Pharmaceuticals' (RXRX) quarterly Depreciation and Depletion came in at $6.2 million in Q4 2024, up 47.62% YoY from $4.2 million in Q1 2024, and up 55.0% on a QoQ basis from $4.0 million in Q3 2024.
Recursion Pharmaceuticals (RXRX) Depreciation and Depletion (2020 - 2024) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 5 years of Depreciation and Depletion data on file, last reported at $6.2 million in Q4 2024.
- Quarterly Depreciation and Depletion rose 47.62% year-over-year to $6.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $18.3 million (up 14.38% YoY) and the FY2025 annual result came in at $33.7 million, up 84.15% from the prior year.
- Depreciation and Depletion grew to $6.2 million in Q4 2024, from $4.0 million in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $6.2 million in Q4 2024 to a low of $1.0 million in Q1 2020.
- A 5-year average of $2.9 million and a median of $2.8 million in 2022 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2021 — Depreciation and Depletion jumped 140.0% — and 2024, when it fell 4.76%.
- Tracing RXRX's Depreciation and Depletion over 5 years: stood at $1.1 million in 2020, then surged by 127.27% to $2.5 million in 2021, then grew by 24.0% to $3.1 million in 2022, then soared by 35.48% to $4.2 million in 2023, then surged by 47.62% to $6.2 million in 2024.
- The last three Depreciation and Depletion figures came in at $6.2 million (Q4 2024), $4.0 million (Q3 2024), and $4.1 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 38.91 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6.20 Mn |
| Dec 31, 2024 | 6.20 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 4.10 Mn |
| Mar 31, 2024 | 4.00 Mn |
| Mar 31, 2024 | 4.00 Mn |
| Dec 31, 2023 | 4.20 Mn |
| Dec 31, 2023 | 4.20 Mn |
| Sep 30, 2023 | 4.20 Mn |
| Sep 30, 2023 | 4.20 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Mar 31, 2023 | 3.60 Mn |
| Mar 31, 2023 | 3.60 Mn |
| Dec 31, 2022 | 3.10 Mn |
| Dec 31, 2022 | 3.10 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Sep 30, 2022 | 2.90 Mn |